JAK/STAT in leukemia: a clinical update
Dong Liang, Qiao-Li Wang, Wenbiao Zhang, Hailin Tang, Cailu Song, Zhimin Yan, Yang Liang, Hua Wang
Abstract
Over the past three decades, considerable efforts have been expended on understanding the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in leukemia, following the identification of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs). The aim of this review is to summarize the latest progress in our understanding of the involvement of the JAK/STAT signaling pathway in the development of leukemia. We also attempt to provide insights into the current use of JAK/STAT inhibitors in leukemia therapy and explore pertinent clinical trials in this field.
Topics & Concepts
statJanus kinaseJAK-STAT signaling pathwaySTAT proteinLeukemiaBiologyCancer researchRuxolitinibMyeloproliferative DisordersSignal transductionImmunologySTAT3MyelofibrosisTyrosine kinaseGeneticsBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsCytokine Signaling Pathways and Interactions